{"id":"vimovo-250-20","safety":{"commonSideEffects":[{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Gastric ulcer (reduced vs. NSAID alone)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3663534","moleculeType":"Small molecule","molecularWeight":"402.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naproxen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Esomeprazole suppresses gastric acid secretion by inhibiting the H+/K+-ATPase pump, protecting the gastric mucosa from NSAID-related damage and ulceration.","oneSentence":"VIMOVO combines naproxen (an NSAID) with esomeprazole (a proton pump inhibitor) to reduce pain and inflammation while protecting the stomach from NSAID-induced ulcers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:18.568Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk for NSAID-induced gastric ulcers"}]},"trialDetails":[{"nctId":"NCT01544114","phase":"PHASE4","title":"A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-04","conditions":"Juvenile Idiopathic Arthritis (JIA)","enrollment":46},{"nctId":"NCT01358383","phase":"PHASE1","title":"Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["naproxen/esomeprazole"],"phase":"marketed","status":"active","brandName":"VIMOVO 250/20","genericName":"VIMOVO 250/20","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VIMOVO combines naproxen (an NSAID) with esomeprazole (a proton pump inhibitor) to reduce pain and inflammation while protecting the stomach from NSAID-induced ulcers. Used for Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients at risk for NSAID-induced gastric ulcers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}